Document Detail


Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.
MedLine Citation:
PMID:  22888220     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hemolytic uremic syndrome is the leading cause of acute kidney injury in childhood. Ninety percent of cases are secondary to gastrointestinal infection with shigatoxin-producing bacteria. In this review, we discuss the molecular mechanisms of shigatoxin leading to hemolytic uremic syndrome and the emerging role of the complement system and vascular endothelial growth factor in its pathogenesis. We also review the evidence for treatment options to date, in particular antibiotics, plasma exchange, and immunoadsorption, and link this to the molecular pathology. Finally, we discuss future avenues of treatment, including shigatoxin-binding agents and complement inhibitors, such as eculizumab.
Authors:
Lindsay S Keir; Stephen D Marks; Jon Jin Kim
Publication Detail:
Type:  Journal Article; Review     Date:  2012-07-19
Journal Detail:
Title:  Drug design, development and therapy     Volume:  6     ISSN:  1177-8881     ISO Abbreviation:  Drug Des Devel Ther     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-13     Completed Date:  2012-10-29     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  101475745     Medline TA:  Drug Des Devel Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  195-208     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Kidney Injury / etiology
Animals
Anti-Bacterial Agents / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Bacterial Infections / complications,  microbiology
Child
Gastrointestinal Diseases / complications*,  microbiology
Hemolytic-Uremic Syndrome / complications,  etiology,  therapy*
Humans
Immunosorbent Techniques
Plasma Exchange / methods
Shiga Toxins*
Grant Support
ID/Acronym/Agency:
G0901987//Medical Research Council
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antibodies, Monoclonal, Humanized; 0/Shiga Toxins; A3ULP0F556/eculizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The preventive role of transurethral antibiotic delivery in a rat model.
Next Document:  Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the p...